Sanofi's Kevzara Phase 3 Trial for Covid-19 Failed to Meet Primary Endpoint
01 September 2020 - 3:52PM
Dow Jones News
By Giulia Petroni
Sanofi SA said Tuesday the Phase 3 trial investigating the use
of Kevzara in severely or critically ill Covid-19 patients didn't
meet its primary endpoint and key secondary endpoint.
The 420-patient randomized trial, which was conducted outside
the U.S., was investigating the administration of Kevzara
intravenously at a dose of 200 milligrams or 400 milligrams, the
French pharmaceutical company said.
Sanofi and Regeneron Pharmaceuticals Inc. aren't planning to
conduct further clinical studies for the use of Kevzara in patients
affected by Covid-19, the company said.
Kevzara is a treatment for adults with moderate to severe active
rheumatoid arthritis who haven't responded to or tolerated previous
therapy.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
September 01, 2020 01:37 ET (05:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024